Reliance Life Sciences is a diverse and integrated biotechnology initiative of the Reliance Group of companies. The Reliance Group is India’s largest private sector enterprise, with annual revenues of US$ 66.8 billion. The Group’s activities span oil and gas exploration and production, petroleum refining, petrochemicals, polyester, plastics, organized retailing and telecom. The Group’s flagship company Reliance Industries Limited is the largest private sector company and a Fortune Global 500 company. Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. RLS was established to develop business opportunities in medical biotechnology with key initiatives in biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical research and molecular diagnostics.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

S.Biomedics Co. Ltd. operates as a biotechnology company. It engages in the research and development of cell therapies for regenerative biomedicine. The company was founded in August 2003 and is headquartered in Seoul, South Korea.

Cellivery’s therapeutic drug candidates are being developed for the prevention of life-threatening lethal diseases, including various cancer. The company’s subsequent drug discovery programs will focus on other diseases, in which the transient suppression of either symptoms or etiology would produce long-term benefits, that are both cost-effective and associated with a high quality of life. Cellivery Therapeutics Inc. was founded by Dr. Daewoong Jo, President and CEO in March of 2014. Its earliest notions have been prepared, however, when Dr. Jo began to study for his doctoral thesis at Vanderbilt University, Nashville, TN, USA in 1997.

McLean Hospital was founded on Feb. 25, 1811, through a charter granted by the Massachusetts Legislature for the “Massachusetts General Hospital Corporation.” From its inception, the Corporation intended to treat both physical and mental illnesses, with a separate facility for each. Fundraising campaigns were held between 1812 and 1816, and a majority of the contributors earmarked their donations for the establishment of a facility to treat mental illnesses. McLean Hospital is dedicated to improving the lives of people and families affected by psychiatric illness. McLean Hospital is a comprehensive mental health care facility committed to providing a full range of high quality, cost effective, mental health services. At McLean Hospital, their staff, faculty, volunteers and supporters are dedicated to improving the lives of people and families affected by psychiatric illness. As the largest psychiatric affiliate of Harvard Medical School, McLean has been meeting the needs of individuals and families with psychiatric illness since their founding in 1811. McLean Hospital's staff of more than 1,900 caring and compassionate individuals are each dedicated to improving the lives of people living with mental illness and their families. McLean Hospital is an affiliate of Harvard Medical School and a member of Partners Healthcare. McLean Hospital is the largest psychiatric teaching facility of Harvard Medical School.

Yuesai Biotechnology is a cell therapy drug developer that uses human pluripotent stem cell technology. Yuesai Biotechnology develops stem cell therapy for neurodegenerative diseases, rare diseases, and tumors using its proprietary intellectual property rights of human pluripotent stem cell preparation, cultivation, differentiation, and gene editing technology platform.

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.

John Wyeth & Bros Ltd. manufactures pharmaceutical products. Its products include protein therapeutics, the rheumatoid arthritis treatment Enbrel, the influenza vaccines Begrivac, and Agrippal medications for depression, hemophilia, cancer and bacterial infections. The company was founded in 1960 by John Wyeth and is headquartered in Taplow, the United Kingdom.

International Stem Cell Corp. operates as a clinical stage biotechnology company. The firm engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market and Therapeutic Market. The Cosmetic Market segment develops, manufactures and markets cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment is involved in the development, manufacture and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Ningbo Yisai Teng Biotechnology Co., Ltd., established on 2018-12-04, Business scope includes biotechnology,Biomedical Science,Technical development of pharmaceutical products,technical consulting,Technical Services,Technology transfer and related product sales;laboratory reagent,Consumables,Instrument sales;Own Equipment Rental Service;Exhibition display service;Corporate Event Planning;Self-operated and agent import and export of various goods and technologies,Except for goods and technologies that are restricted by the state or prohibited from import and export;and other legal,regulations,Projects that are not prohibited or do not require operating permits and projects that are not included in the negative list of local industrial development in the decision of the State Council.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Guangzhou Ruizhen Regenerative Medicine Technology Co., Ltd., established on 2019-01-31, Business scope includes research and development of biological products(Does not include licensed operations);Stem Cell Drug Development;Stem Cell Technology Research,to develop;Biotechnology Consulting,communication service;Biotechnology Development Services;Health Management Consulting Services(Medical treatment activities subject to approval,Except for psychological counseling,Does not include licensed operations,Projects prohibited by laws and regulations shall not be operated);Medical supplies and equipment retail(Does not contain drugs and medical devices);Import and export(Excluding franchised products);Sales of Biological Products(Does not include licensed operations);Sales of biological diagnostic reagents and kits(Does not include license approval items);Manufacture of stem cell series technical engineering products;Sales of stem cell series technical engineering products;Manufacture of stem cell engineering series products;Sales of stem cell engineering series products;Preparation of cell preparations and related products;Sales of cell preparations and related products;Stem Cell Biotechnology Consulting Services;Stem Cell Biotechnology Transfer Services;Stem Cell Biotechnology Services;collection of stem cells,storage,preparation service(Without umbilical cord blood hematopoietic stem cell collection,storage);Genetic testing and disease screening services;Collection of immune cells,storage,preparation service(Without umbilical cord blood hematopoietic stem cell collection,storage);Technology development of stem cell engineering series products;Research and development of stem cell series technical engineering products

Generon (Shanghai) Corporation Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Their research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. their cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China. Their mission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs. They employ their proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. They are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. They follow international quality standards for their product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing.